Previous close | 3.5300 |
Open | 3.5900 |
Bid | 3.6700 x 400 |
Ask | 3.7500 x 100 |
Day's range | 3.4700 - 3.7000 |
52-week range | 1.3700 - 9.8000 |
Volume | |
Avg. volume | 825,080 |
Market cap | 194.379M |
Beta (5Y monthly) | 2.13 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.9700 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.25 |
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that nine scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, being held from May 5 – 9 in Seattle, Washington.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.